Announced Mon, 29 Sept · 17:20 IST

Proceedings of the 33rd Annual General Meeting held on 29th September, 2025

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Indrayani Biotech held its 33rd AGM on September 29, 2025 via video conferencing, chaired by Managing Director Mr. Kasiraman Sayee Sundar, which concluded in 27 minutes. Shareholders transacted 18 resolutions, including adoption of audited financial statements for FY25 and re-appointment of three whole-time directors including the Managing Director. A key item was approval to increase the company's Authorised Share Capital from Rs. 65 Crores to Rs. 85 Crores (after rescinding a prior resolution). The meeting also cleared material related-party transactions of up to Rs. 25 Crores each with six subsidiaries/related entities (Dindigul Farm Product, Matrix Boilers, IBL Healthcare, HSL Agri Solutions, HSLPrime Properties, and IBL Investments), approved the appointment of a new Independent Director and a Secretarial Auditor for five years, and cleared a disinvestment from subsidiary Dindigul Farm Product Limited.

Likely market impact

The Rs. 20 Crore hike in authorised share capital signals potential fundraising plans ahead, while multiple large related-party transactions with subsidiaries point to active inter-group dealings that investors should monitor. The proposed disinvestment from Dindigul Farm Product and continued re-appointment of the existing management team indicate strategic restructuring with continuity at the top.